Literature DB >> 30456984

Long term survival after early unloading with Impella CP® in acute myocardial infarction complicated by cardiogenic shock.

Tobias Loehn1, William W O'Neill2, Bjoern Lange1, Christian Pfluecke1, Tina Schweigler1, Johannes Mierke1, Nadine Waessnig1, Adrian Mahlmann1, Akram Youssef1, Uwe Speiser1, Ruth H Strasser1, Karim Ibrahim1.   

Abstract

BACKGROUND: The use of percutaneous left ventricular assist devices in patients with acute myocardial infarction complicated by cardiogenic shock (AMICS) is evolving. The aim of the study was to assess the long-term outcome of patients with AMICS depending on early initiation of Impella CP® support prior to a percutaneous coronary intervention (PCI).
METHODS: We retrospectively reviewed all patients who underwent PCI and Impella CP® support between 2014 and 2016 for AMICS at our institution. We compared survival to discharge between those with support initiation before (pre-PCI) and after (post-PCI) PCI.
RESULTS: A total of 73 consecutive patients (69±12 years old, 27.4% female) were supported with Impella CP® and underwent PCI for AMICS (34 pre-PCI vs. 39 post-PCI). All patients were admitted with cardiogenic shock, and 58.9% sustained cardiac arrest. Survival at discharge was 35.6%. Compared with the post-PCI group, patients in the pre-PCI group had more lesions treated (p=0.03), a higher device weaning rate (p=0.005) and higher survival to discharge as well as to 30 and 90 days after device implantation, respectively (50.0% vs. 23.1%, 48.5% vs. 23.1%, 46.9 vs. 20.5%, p < 0.05). Kaplan-Meier analysis showed a higher survival at one year (31.3% vs. 17.6%, log-rank p-value=0.03) in the pre-PCI group. Impella support initiation before PCI was an independent predictor of survival up to 180 days after device implantation.
CONCLUSIONS: In this small, single-centre, non-randomized study Impella CP® initiation prior to PCI was associated with higher survival rates at discharge and up to one year in AMICS patients presenting with high risk for in-hospital mortality.

Entities:  

Keywords:  Cardiogenic shock; NSTEMI; STEMI; acute coronary syndrome; percutaneous left ventricular assist device

Mesh:

Year:  2018        PMID: 30456984     DOI: 10.1177/2048872618815063

Source DB:  PubMed          Journal:  Eur Heart J Acute Cardiovasc Care        ISSN: 2048-8726


  10 in total

1.  Impella®: an updated meta-analysis of available data and future outlook on applications in cardiogenic shock.

Authors:  Bernhard Wernly; Alexander Lauten; Holger Thiele; Christian Jung
Journal:  Wien Klin Wochenschr       Date:  2020-01-16       Impact factor: 1.704

2.  Mechanical circulatory support with Impella versus intra-aortic balloon pump or medical treatment in cardiogenic shock-a critical appraisal of current data.

Authors:  Bernhard Wernly; Clemens Seelmaier; David Leistner; Barbara E Stähli; Ingrid Pretsch; Michael Lichtenauer; Christian Jung; Uta C Hoppe; Ulf Landmesser; Holger Thiele; Alexander Lauten
Journal:  Clin Res Cardiol       Date:  2019-03-21       Impact factor: 5.460

Review 3.  Mechanical Circulatory Support for Acute Heart Failure Complicated by Cardiogenic Shock.

Authors:  Min Suk Choi; Hunbo Shim; Yang Hyun Cho
Journal:  Int J Heart Fail       Date:  2020-01-22

4.  Impella in cardiogenic shock following acute myocardial infarction: a systematic review and meta-analysis.

Authors:  Kris G Vargas; Bernhard Jäger; Christoph C Kaufmann; Andrea Biagioli; Stephan Watremez; Fernando Gatto; Cem Özbek; Amjad Razouk; Alexander Geppert; Kurt Huber
Journal:  Wien Klin Wochenschr       Date:  2020-07-20       Impact factor: 1.704

Review 5.  Contemporary device management of cardiogenic shock following acute myocardial infarction.

Authors:  Tariq Suleiman; Alexander Scott; David Tong; Vikram Khanna; Vijay Kunadian
Journal:  Heart Fail Rev       Date:  2021-03-03       Impact factor: 4.214

6.  Association between the Door-to-balloon Time and Mid-term Clinical Outcomes in Patients with ST-Segment Elevation Myocardial Infarction.

Authors:  Takunori Tsukui; Kenichi Sakakura; Yousuke Taniguchi; Kei Yamamoto; Masaru Seguchi; Hiroshi Wada; Shin-Ichi Momomura; Hideo Fujita
Journal:  Intern Med       Date:  2020-07-01       Impact factor: 1.271

7.  Impella versus extracorporal life support in cardiogenic shock: a propensity score adjusted analysis.

Authors:  Bernhard Wernly; Mina Karami; Annemarie E Engström; Stephan Windecker; Lukas Hunziker; Thomas F Lüscher; Jose P Henriques; Markus W Ferrari; Stephan Binnebößel; Maryna Masyuk; David Niederseer; Peter Abel; Georg Fuernau; Marcus Franz; Malte Kelm; Mathias C Busch; Stephan B Felix; Holger Thiele; Alexander Lauten; Christian Jung
Journal:  ESC Heart Fail       Date:  2021-02-09

8.  Long-Term Clinical Outcome of Cardiogenic Shock Patients Undergoing Impella CP Treatment vs. Standard of Care.

Authors:  Clemens Scherer; Enzo Lüsebrink; Danny Kupka; Thomas J Stocker; Konstantin Stark; Christopher Stremmel; Mathias Orban; Tobias Petzold; Antonia Germayer; Katharina Mauthe; Stefan Kääb; Julinda Mehilli; Daniel Braun; Hans Theiss; Stefan Brunner; Jörg Hausleiter; Steffen Massberg; Martin Orban
Journal:  J Clin Med       Date:  2020-11-24       Impact factor: 4.241

9.  Comparison of Mortality Risk Models in Patients with Postcardiac Arrest Cardiogenic Shock and Percutaneous Mechanical Circulatory Support.

Authors:  Georgios Chatzis; Birgit Markus; Styliani Syntila; Christian Waechter; Ulrich Luesebrink; Holger Ahrens; Dimitar Divchev; Bernhard Schieffer; Konstantinos Karatolios
Journal:  J Interv Cardiol       Date:  2021-01-18       Impact factor: 2.279

10.  Predictive value of the APACHE II score in cardiogenic shock patients treated with a percutaneous left ventricular assist device.

Authors:  Johannes Mierke; Thomas Nowack; Tobias Loehn; Franziska Kluge; Frederike Poege; Uwe Speiser; Felix Woitek; Norman Mangner; Karim Ibrahim; Axel Linke; Christian Pfluecke
Journal:  Int J Cardiol Heart Vasc       Date:  2022-03-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.